<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacy (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacy (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmacy</journal-id><journal-title-group><journal-title>Pharmacy</journal-title></journal-title-group><issn pub-type="epub">2226-4787</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407505</article-id><article-id pub-id-type="pmc">PMC12101176</article-id>
<article-id pub-id-type="doi">10.3390/pharmacy13030067</article-id><article-id pub-id-type="publisher-id">pharmacy-13-00067</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Declines in Tapentadol Use in the US but Pronounced Regional Variation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Low</surname><given-names>Ching Y.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmacy-13-00067" ref-type="aff">1</xref><xref rid="af2-pharmacy-13-00067" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2061-108X</contrib-id><name><surname>McCall</surname><given-names>Kenneth L.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af3-pharmacy-13-00067" ref-type="aff">3</xref><xref rid="af4-pharmacy-13-00067" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2295-445X</contrib-id><name><surname>Piper</surname><given-names>Brian J.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmacy-13-00067" ref-type="aff">1</xref><xref rid="af5-pharmacy-13-00067" ref-type="aff">5</xref><xref rid="c1-pharmacy-13-00067" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Rao</surname><given-names>Shantanu</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmacy-13-00067"><label>1</label>Department of Medical Education, Geisinger College of Health Sciences, Scranton, PA 18509, USA; <email>sherynqylow@outlook.com</email></aff><aff id="af2-pharmacy-13-00067"><label>2</label>School of Medicine, Rutgers New Jersey Medical School, Newark, NJ 07103, USA</aff><aff id="af3-pharmacy-13-00067"><label>3</label>Department of Pharmacy Practice, Binghamton University, Johnson City, NY 13790, USA; <email>kmccall@binghamton.edu</email></aff><aff id="af4-pharmacy-13-00067"><label>4</label>Department of Pharmacy Practice, University of New England, Biddeford, ME 04005, USA</aff><aff id="af5-pharmacy-13-00067"><label>5</label>Center for Pharmacy Innovation &#x00026; Outcomes, Geisinger College of Health Sciences, Danville, PA 17821, USA</aff><author-notes><corresp id="c1-pharmacy-13-00067"><label>*</label>Correspondence: <email>bjpiper1@geisinger.edu</email>; Tel.: +1-413-347-7199</corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>13</volume><issue>3</issue><elocation-id>67</elocation-id><history><date date-type="received"><day>13</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>05</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>08</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background: Tapentadol is an atypical opioid with a dual mechanism as a mu agonist and norepinephrine reuptake inhibitor. This study characterized tapentadol use in the United States (US) using three databases. Methods: Drug distribution data from 2010 to 2020 were extracted from the Drug Enforcement Administration (DEA)&#x02019;s Automated Reports and Consolidated Orders System (ARCOS), including use per region (mg/person) and business activity (i.e., pharmacy). Tapentadol prescription claims from the Medicare and Medicaid programs for 2010&#x02013;2020 were also examined. Results: The distributed amount of tapentadol was 3.5 tons in 2020. Distribution was over twice as high in southern (South Atlantic = 29.0 mg/person, East South Central = 28.8) relative to Pacific (12.9) or New England (12.8) states. Tapentadol use decreased nationally between 2012 and 2020 by &#x02212;53.8%. Adult diabetes prevalence was significantly associated with tapentadol distribution in 2012 (r(50) = +0.44, <italic toggle="yes">p</italic> &#x0003c; 0.01) and 2020 (r(50) = +0.28, <italic toggle="yes">p</italic> &#x0003c; 0.05). Tapentadol prescribing to Medicaid patients declined &#x02212;55.2% from the peak year, 2011, until 2020. Tapentadol prescribed by Nurse Practitioners accounted for over one-sixth (18.0%) of 2019 in Medicare. Conclusions: There has been a substantial decline over the past decade in tapentadol distribution and prescribing. However, the substantial regional differences may warrant further attention by opioid stewardship programs.</p></abstract><kwd-group><kwd>ARCOS</kwd><kwd>diabetes</kwd><kwd>opiate</kwd><kwd>opioid</kwd><kwd>pain</kwd><kwd>pharmacoepidemiology</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmacy-13-00067"><title>1. Introduction</title><p>Over one million overdoses have been attributed to the US opioid epidemic [<xref rid="B1-pharmacy-13-00067" ref-type="bibr">1</xref>]. There is an ongoing need for other pharmacotherapies to treat acute and chronic pain which may be less likely to be misused and diverted than selective &#x000b5; opioid receptor (MOR) agonists. Tapentadol is a synthetic, centrally acting analgesic that combines agonist activity at MOR with norepinephrine reuptake inhibition (NRI). Tapentadol had similar affinity for the human norepinephrine (1.3 &#x003bc;M) and serotonin transporter (3.3 &#x003bc;M) [<xref rid="B2-pharmacy-13-00067" ref-type="bibr">2</xref>]. The tapentadol immediate release (IR) formulation was approved in 2008 for acute pain in adults (&#x02265;18) severe enough to warrant an opioid analgesic, whereas tapentadol extended release (ER) was approved in 2013 for around-the-clock, long-term treatment for severe chronic pain and severe pain associated with diabetic peripheral neuropathy in the US. However, the American Diabetes Association does not recommend tapentadol as either a first or second line for diabetic neuropathy due to safety concerns such as the risk of addiction and relatively modest pain reduction [<xref rid="B3-pharmacy-13-00067" ref-type="bibr">3</xref>]. Similarly, the 2020 National Institute for Health and Care Excellence guidelines on the management of neuropathic pain in adults in non-specialist settings do not address a place in therapy for tapentadol [<xref rid="B4-pharmacy-13-00067" ref-type="bibr">4</xref>]. The common adverse effects of tapentadol IR were somnolence and nausea, while ER produced vomiting, constipation, and dizziness [<xref rid="B3-pharmacy-13-00067" ref-type="bibr">3</xref>]. Analysis of a World Health Organization database identified 42 cases of serotonin syndrome where tapentadol was the single causative agent [<xref rid="B2-pharmacy-13-00067" ref-type="bibr">2</xref>]. The US Drug Enforcement Administration (DEA) classified tapentadol as a Schedule II controlled substance [<xref rid="B5-pharmacy-13-00067" ref-type="bibr">5</xref>], although tapentadol ER cost less than other Schedule II opioids when sold illicitly [<xref rid="B6-pharmacy-13-00067" ref-type="bibr">6</xref>].</p><p>Prior pharmacoepidemiological research has examined typical opioids including fentanyl [<xref rid="B7-pharmacy-13-00067" ref-type="bibr">7</xref>], hydrocodone [<xref rid="B8-pharmacy-13-00067" ref-type="bibr">8</xref>], meperidine [<xref rid="B9-pharmacy-13-00067" ref-type="bibr">9</xref>], and methadone [<xref rid="B10-pharmacy-13-00067" ref-type="bibr">10</xref>], but less is known for tapentadol. The purpose of this study was to investigate the pattern in tapentadol&#x02019;s distribution and prescriptions in the US from 2010 through 2020. This interval includes when there have been pronounced corrections in earlier excesses in US opioid prescribing [<xref rid="B8-pharmacy-13-00067" ref-type="bibr">8</xref>] but also continued increases in obesity and diabetes. Three complementary datasets, including the Automation of Reports and Consolidated Orders Systems (ARCOS) published by the DEA [<xref rid="B11-pharmacy-13-00067" ref-type="bibr">11</xref>,<xref rid="B12-pharmacy-13-00067" ref-type="bibr">12</xref>], Medicaid [<xref rid="B13-pharmacy-13-00067" ref-type="bibr">13</xref>], and Medicare Part D [<xref rid="B14-pharmacy-13-00067" ref-type="bibr">14</xref>] programs, were used. This study also characterized the distribution of tapentadol relative to other Schedule II opioids to further understand tapentadol&#x02019;s distribution in the context of additional opioid US prescribing regulations [<xref rid="B15-pharmacy-13-00067" ref-type="bibr">15</xref>]. Examination of the correlation between the adult prevalence of diabetes [<xref rid="B16-pharmacy-13-00067" ref-type="bibr">16</xref>] and tapentadol distribution was also determined. This report also attempted to validate ARCOS by examining the correspondence with Medicaid.</p></sec><sec id="sec2-pharmacy-13-00067"><title>2. Materials and Methods</title><p>Procedures: Three complementary datasets (the DEA&#x02019;s production quotas/ARCOS, Medicaid, and Medicare) were obtained for this observational report. Tapentadol and other Schedule II opioids (codeine, fentanyl, hydrocodone, hydromorphone, meperidine, morphine, oxycodone, oxymorphone) were extracted from the DEA&#x02019;s ARCOS, a comprehensive drug reporting database containing an annually updated report of the distribution of DEA controlled substances from manufacturers and distributors to pharmacies and hospitals. ARCOS has been used in prior pharmacoepidemiology studies and showed a strong (r = 0.985) correlation with a state prescription drug monitoring program for oxycodone [<xref rid="B8-pharmacy-13-00067" ref-type="bibr">8</xref>]. We extracted tapentadol (g) by state, quarter, and retail distribution via hospitals, pharmacies, practitioners, and teaching institutions [<xref rid="B11-pharmacy-13-00067" ref-type="bibr">11</xref>]. The annual final adjusted production quota (g) of tapentadol was also extracted from the DEA [<xref rid="B12-pharmacy-13-00067" ref-type="bibr">12</xref>].</p><p>Data for covered outpatient drugs paid by state Medicaid agencies have been reported to the Centers for Medicare and Medicaid Services (CMS) and captured in the State Drug Utilization Data (SDUD) database [<xref rid="B13-pharmacy-13-00067" ref-type="bibr">13</xref>]. We extracted Medicaid claims for tapentadol including the corresponding 11-digit National Drug Code (NDC) for every tapentadol claim in each quarter from 2013 to 2019. We determined the milligrams per tablet from the NDC Directory [<xref rid="B17-pharmacy-13-00067" ref-type="bibr">17</xref>] and thereafter computed the tapentadol (grams) reimbursed per entry. Total distributed tapentadol in grams using ARCOS and Medicaid data were converted to metric tons. Prescriber state and provider specialty type were extracted for tapentadol from Medicare Part D Prescriber Data from the Centers for Medicare and Medicaid Services from 2013 through 2019 [<xref rid="B14-pharmacy-13-00067" ref-type="bibr">14</xref>], the most recent year available, to compute Medicare claims on tapentadol aggregated by prescribers&#x02019; specialty and the state the prescribers were located in.</p><p>The FDA labeling for tapentadol cautions use in pediatric patients as the safety and efficacy have not been established in this population [<xref rid="B18-pharmacy-13-00067" ref-type="bibr">18</xref>]. We found no prescription orders of tapentadol to anyone younger than 18 by the Geisinger Health System, which served three million patients, between 2009 and 2020. Therefore, we calculated tapentadol (mg/person) using estimates of people aged 18 and above from 2010 to 2020 extracted from the US Census Bureau, Population Division [<xref rid="B19-pharmacy-13-00067" ref-type="bibr">19</xref>].</p><p>The morphine milligrams equivalent (MME) for each Schedule II opioid was determined. Conversions were completed with the multipliers of [<xref rid="B8-pharmacy-13-00067" ref-type="bibr">8</xref>] codeine, 0.15; fentanyl, 75; hydrocodone, 1; hydromorphone, 4; meperidine, 0.1; morphine, 1; oxycodone, 1.5; oxymorphone, 3; and tapentadol, 0.4, which have also been employed in prior pharmacoepidemiological reports [<xref rid="B7-pharmacy-13-00067" ref-type="bibr">7</xref>,<xref rid="B8-pharmacy-13-00067" ref-type="bibr">8</xref>,<xref rid="B9-pharmacy-13-00067" ref-type="bibr">9</xref>,<xref rid="B10-pharmacy-13-00067" ref-type="bibr">10</xref>,<xref rid="B11-pharmacy-13-00067" ref-type="bibr">11</xref>]. The diabetes prevalence was retrieved to compute adult diabetes diagnosed per 100 people in each state [<xref rid="B16-pharmacy-13-00067" ref-type="bibr">16</xref>]. Institutional Review Board approval was obtained from Geisinger (2021&#x02013;0312, Approved 13 March 2021) and the University of New England (CR00001291, Approved 12 December 2022).</p><p>Statistics: GraphPad Prism (Boston, MA, USA, version 10.2.0: <uri xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</uri> accessed on 7 May 2025) and Microsoft Excel (Redmond, WA, USA, version 2312, <uri xlink:href="https://www.microsoft.com/en-us/">https://www.microsoft.com/en-us/</uri> accessed 7 May 2025 ) were used to graph and analyze the data. We identified the peak year and expressed ARCOS and Medicaid findings as the percent change relative to this peak. Results were displayed on a heatmap (<uri xlink:href="http://www.heatmapper.ca/">http://www.heatmapper.ca/</uri> accessed on 7 May 2025). As has been done previously [<xref rid="B7-pharmacy-13-00067" ref-type="bibr">7</xref>], percentage change values were deemed significant if &#x02265;1.96 standard deviations above or below the mean. Tapentadol by retail distributors including hospitals, pharmacies, practitioners, and teaching institutions was expressed as the percent of the total for each year. A <italic toggle="yes">t</italic>-test between distributed tapentadol and the final adjusted production quota was performed. Regional analysis was conducted by dividing ARCOS aggregate data per US Census divisions (New England, Middle Atlantic, East North Central, West North Central, South Atlantic, East South Central, West South Central, Mountain, Pacific). The distribution pattern for tapentadol relative to that of other Schedule II opioids was determined at the national level and separately for a particularly atypical state (New Hampshire). Analysis of the correlation between ARCOS and Medicaid data was completed to provide information about the validity of ARCOS. Aggregate claims grouped by prescriber specialty and state using Medicare data were presented as percentages for each year. Adult diabetes diagnoses per 100 persons were correlated with tapentadol (mg/person aged &#x0003e;18) from ARCOS at the national level and within each state. A <italic toggle="yes">p</italic> &#x0003c; 0.05 was considered statistically significant.</p></sec><sec sec-type="results" id="sec3-pharmacy-13-00067"><title>3. Results</title><p>Between 2012, the peak year, and 2020, tapentadol saw a &#x02212;53.8% reduction in the US as reported to ARCOS. In the same period, other Schedule II opioids also showed declines, with meperidine having the most reduction (&#x02212;91.8%), and codeine the least (&#x02212;32.1%; <xref rid="pharmacy-13-00067-f001" ref-type="fig">Figure 1</xref>A). On average, the final adjusted quota from ARCOS was 207.2% greater than the distributed amount, and this difference was significant (<xref rid="pharmacy-13-00067-f001" ref-type="fig">Figure 1</xref>B).</p><p>The distribution of Schedule II opioids in MME determined that oxycodone accounted for nearly half of 2020&#x02019;s distribution, while tapentadol accounted for 1.3%. The percent distribution of opioids was relatively constant in 2012 and 2020 (<xref rid="pharmacy-13-00067-f001" ref-type="fig">Figure 1</xref>C). The amount of tapentadol distributed by each business activity showed modest variation between 2010 and 2020. Pharmacies were consistently the predominant distribution channel (98.0% in 2010 and 98.1% in 2020). Hospitals increased from 1.1% to 1.9% of distribution, and this gain was achieved with a corresponding decrease among practitioners (<xref rid="pharmacy-13-00067-f001" ref-type="fig">Figure 1</xref>D).</p><p>A regional analysis revealed that tapentadol distribution to New England and the Pacific states was less than half of the East South Central and South Atlantic states (<xref rid="pharmacy-13-00067-f002" ref-type="fig">Figure 2</xref>A). Exploratory analyses determined that the New England and Pacific states were significantly lower than all other US Census divisions except the West North Central (<xref rid="pharmacy-13-00067-f002" ref-type="fig">Figure 2</xref>B).</p><p>Every state in the US saw a reduction in tapentadol between 2012 and 2020, except for New Hampshire (NH, +13.1% increase, <xref rid="pharmacy-13-00067-f003" ref-type="fig">Figure 3</xref>A). The percent changes for Idaho (&#x02212;14.7%) and NH were outside the 95% confidence interval (<xref rid="pharmacy-13-00067-f003" ref-type="fig">Figure 3</xref>B). A correlation analysis on ARCOS with Medicaid showed a strong, positive, and significant correlation of 0.80 (<xref rid="pharmacy-13-00067-f004" ref-type="fig">Figure 4</xref>A).</p><p>Tapentadol prescription claims from Medicaid mirrored the distribution reported by ARCOS. Medicaid prescriptions peaked in the second quarter of 2011, and there was an appreciable decrease (&#x02212;55.2%) from then until the end of 2020 (<xref rid="pharmacy-13-00067-f004" ref-type="fig">Figure 4</xref>B).</p><p>Next, tapentadol claims from Medicare Part D were presented as a percentage for each year by prescribing specialties. Nurse Practitioners experienced a strong and steady increase in their share of tapentadol&#x02019;s prescriptions and became the specialty with the largest portion in 2019. NPs accounted for 9.3% in 2013 but doubled to 18.0% in 2019. Physician Assistants experienced a steady but more moderate increase from 9.3% in 2013 to 14.5% in 2019 (<xref rid="pharmacy-13-00067-f005" ref-type="fig">Figure 5</xref>).</p><p>Because NH was atypical in ARCOS, exploratory analyses were completed for this state. Certified Registered Nurse Anesthetists (CRNAs) saw a steep increase from 16.9% in 2013 to 59.7% in 2015, followed by a pronounced decline to 5.3% in 2019. Nurse Practitioners showed a strong increase in the share of prescriptions after the dip between 2013 and 2016, where it became the specialty with the largest share at 36.0% in 2019. Pain management experienced a seven-fold increase from 1.9% in 2013 to 13.7% in 2019 (<xref rid="pharmacy-13-00067-f006" ref-type="fig">Figure 6</xref>).</p><p>Tapentadol&#x02019;s distribution in ARCOS and the diabetes prevalence showed a moderate correlation of 0.44 (<italic toggle="yes">p</italic> &#x0003c; 0.01) for 2012. Similarly, it was 0.28 (<italic toggle="yes">p</italic> &#x0003c; 0.05) for 2020 (<xref rid="pharmacy-13-00067-f007" ref-type="fig">Figure 7</xref>).</p></sec><sec sec-type="discussion" id="sec4-pharmacy-13-00067"><title>4. Discussion</title><p>This novel study identified pronounced, but regionally dependent, changes in the prescribing pattern of tapentadol in the US between 2010 and 2020, with a notable peak in 2012. Using ARCOS data, tapentadol decreased &#x02212;53.8% between 2012 and 2020, and its decrease was ranked fourth among Schedule II opioids (<xref rid="pharmacy-13-00067-f001" ref-type="fig">Figure 1</xref>A). Given that tapentadol is mechanistically unusual for a Schedule II opioid [<xref rid="B2-pharmacy-13-00067" ref-type="bibr">2</xref>] and is approved to treat neuropathic pain associated with adult diabetes, a condition which has increased over the past decade, we wanted to better understand these use patterns. Distribution of tapentadol to New England states was less than half that in the southern US. Significant associations between diabetes prevalence and tapentadol distribution were also observed (<xref rid="pharmacy-13-00067-f007" ref-type="fig">Figure 7</xref>). This correlation was slightly lower in 2020 (r = 0.28) than 2012 (r = 0.44), which might reflect increased use of non-Schedule II alternatives like pregabalin or duloxetine [<xref rid="B3-pharmacy-13-00067" ref-type="bibr">3</xref>] for neuropathic pain among diabetes patients. Similarly, a prior study found that meperidine distribution was moderately (r = 0.48) associated with state level of obesity, with the highest distribution in Arkansas, Alabama, Mississippi, and Louisiana [<xref rid="B9-pharmacy-13-00067" ref-type="bibr">9</xref>].</p><p>There were notable changes in the insurance and policy intervention landscapes in the period surrounding 2012, likely in response to a November 2011 communication from the Centers for Disease Control and Prevention stating that overdoses from prescription opioid painkillers had reached epidemic levels [<xref rid="B20-pharmacy-13-00067" ref-type="bibr">20</xref>]. States adopted policy interventions such as mandated Prescription Drug Monitoring Programs (PDMPs) and pain clinic laws, while the Centers for Medicare and Medicaid Services implemented the Overutilization Monitoring System in 2013 [<xref rid="B21-pharmacy-13-00067" ref-type="bibr">21</xref>]. In addition, private insurers began to take actions to limit the reimbursement of opioids [<xref rid="B22-pharmacy-13-00067" ref-type="bibr">22</xref>]. We recognize success in containing the opioid crisis varies, as do state-level policy interventions, insurance reimbursements, prescription rights, and prescribing behaviors [<xref rid="B7-pharmacy-13-00067" ref-type="bibr">7</xref>,<xref rid="B23-pharmacy-13-00067" ref-type="bibr">23</xref>,<xref rid="B24-pharmacy-13-00067" ref-type="bibr">24</xref>,<xref rid="B25-pharmacy-13-00067" ref-type="bibr">25</xref>].</p><p>Our data showed that all states in the US showed a reduction in the percentage change in the amount of tapentadol distributed between 2012 and 2020, except NH (+13.1%), and this was statistically significantly different from the national average (<xref rid="pharmacy-13-00067-f002" ref-type="fig">Figure 2</xref>B). New Hampshire providers wrote 46.1 opioid prescriptions for every 100 persons in 2018, relative to the average US rate of 51.4 prescriptions [<xref rid="B26-pharmacy-13-00067" ref-type="bibr">26</xref>]. However, tapentadol and methadone were two opioids that did not show similar declining patterns as other opioids. Methadone is approved by the US Food and Drug Administration (FDA) for treating opioid use disorder (OUD), although some formulations are also used for pain [<xref rid="B10-pharmacy-13-00067" ref-type="bibr">10</xref>]. New Hampshire has been expanding the availability of addiction treatment through medication-assisted treatment for OUD [<xref rid="B27-pharmacy-13-00067" ref-type="bibr">27</xref>]. A purported off-label use of tapentadol may include it being used as part of a step-down therapy in treating OUDs [<xref rid="B28-pharmacy-13-00067" ref-type="bibr">28</xref>]. More than 97% of tapentadol distributed in the US from 2010 through 2020 were through pharmacies. This indicates that most tapentadol was prescribed in outpatient services and office settings (<xref rid="pharmacy-13-00067-f001" ref-type="fig">Figure 1</xref>D). Tapentadol distributed by hospitals steadily increased to nearly 2% of the total in 2020, and this observation can be partly explained by anesthesiology as a specialty increasing in its share (13.8%) of the total tapentadol Medicare claims in 2019 (<xref rid="pharmacy-13-00067-f005" ref-type="fig">Figure 5</xref>). A randomized controlled trial in Australia determined that restricting oxycodone in the emergency room resulted in a doubling of tapentadol [<xref rid="B29-pharmacy-13-00067" ref-type="bibr">29</xref>]. Surgery, neurology, and spinal rehabilitation were the most common specialties for tapentadol prescribing in the Prince of Wales hospital in Sydney [<xref rid="B30-pharmacy-13-00067" ref-type="bibr">30</xref>].</p><p>For both US and NH, Nurse Practitioners (NPs) were the specialty that had the largest share of tapentadol prescribed using Medicare Part D data in 2019. NPs prescribed 18.0% of Medicare claims of tapentadol at the national level (<xref rid="pharmacy-13-00067-f005" ref-type="fig">Figure 5</xref>) and 36.0% in NH (<xref rid="pharmacy-13-00067-f006" ref-type="fig">Figure 6</xref>). NPs increased the number of opioids they prescribed following a grant of NP independence [<xref rid="B31-pharmacy-13-00067" ref-type="bibr">31</xref>], and NPs and Physician Assistants (PAs) practicing in states with independent prescription authority had a greater number of outliers who prescribed high-frequency, high dose opioids than did MDs [<xref rid="B32-pharmacy-13-00067" ref-type="bibr">32</xref>]. Prescriptive rights of NPs differ across states. In NH, NPs were granted full authority to prescribe Schedule II to IV controlled substances in 2009 [<xref rid="B33-pharmacy-13-00067" ref-type="bibr">33</xref>]. Our data showed that NPs and CRNAs experienced opposing trends between 2013 and 2019. NPs decreased sharply from 57.1% in 2013 to 10.8% in 2016 then rebounded strongly to 36.0% and ranked first among all specialties in 2019. According to the American Association of Nurse Practitioners, 70.2% of all NPs deliver primary care in 2020 [<xref rid="B34-pharmacy-13-00067" ref-type="bibr">34</xref>], and therefore there is an increased likelihood of NPs caring for chronic but less complex cases.</p><p>It was also noteworthy that tapentadol production quotas [<xref rid="B12-pharmacy-13-00067" ref-type="bibr">12</xref>] were double (207.2%) distribution. The DEA&#x02019;s final adjusted quota seeks to &#x0201c;ensure an adequate and uninterrupted supply of controlled substances in order to meet the demand of legitimate medical, scientific, and export needs of the United States&#x0201d; [<xref rid="B12-pharmacy-13-00067" ref-type="bibr">12</xref>]. Our data suggest the DEA&#x02019;s quota was not a determining factor influencing the amount of tapentadol distributed in the US. Presumably, this was because the DEA&#x02019;s production quota also included tapentadol which was subsequently exported to other countries.</p><p>Tapentadol distribution, when expressed as MME, accounted for a modest portion (1.3%) of the 2020 total for Schedule II substances. However, this amount was greater than that of oxymorphone or meperidine [<xref rid="B9-pharmacy-13-00067" ref-type="bibr">9</xref>]. Meperidine [<xref rid="B35-pharmacy-13-00067" ref-type="bibr">35</xref>], like tapentadol, has been linked to cases of serotonin syndrome [<xref rid="B36-pharmacy-13-00067" ref-type="bibr">36</xref>]. Also similar to meperidine, there have been concerns with tapentadol and neurotoxicity [<xref rid="B37-pharmacy-13-00067" ref-type="bibr">37</xref>]. The atypical mechanism of tapentadol may offer another advantage relative to typical opioids in not inhibiting neurogenesis, at least in rodents [<xref rid="B38-pharmacy-13-00067" ref-type="bibr">38</xref>], but this awaits other human research for verification. The amount of tapentadol reported to the DEA&#x02019;s ARCOS strongly and significantly correlated with the amount of Medicaid claims, at 0.80 (<xref rid="pharmacy-13-00067-f004" ref-type="fig">Figure 4</xref>A), suggesting that tapentadol was employed at a population level broadly similarly for Medicaid and non-Medicaid patient populations.</p><p>Some caveats and future directions should also be considered. A limitation of ARCOS is that tapentadol was reported by weight, with no information on the number of prescriptions or recipients. However, a strength of this report relative to previous ones [<xref rid="B7-pharmacy-13-00067" ref-type="bibr">7</xref>,<xref rid="B8-pharmacy-13-00067" ref-type="bibr">8</xref>,<xref rid="B9-pharmacy-13-00067" ref-type="bibr">9</xref>,<xref rid="B10-pharmacy-13-00067" ref-type="bibr">10</xref>] is the inclusion of prescription information from the Medicaid and Medicare programs. These databases are complementary in providing population-level patterns, but they are not generalizable to patient-level patterns. The high correspondence between ARCOS and Medicaid indicates that opioid distribution is a valid population level measure. Not all analyses (e.g., the comparison of New England vs. other regions) were hypothesized a priori and should be interpreted with caution. Given that tapentadol is not recommended as a first, or even second, line pharmacotherapy for neuropathic pain [<xref rid="B3-pharmacy-13-00067" ref-type="bibr">3</xref>], follow-up studies with electronic health records examining multiple pharmacotherapies may be necessary as the rates of adult diabetes continues to increase [<xref rid="B39-pharmacy-13-00067" ref-type="bibr">39</xref>]. Electronic health records will also be valuable to further characterize whether prescriptions expand to other pain conditions (e.g., fibromyalgia) [<xref rid="B40-pharmacy-13-00067" ref-type="bibr">40</xref>] or to children and adolescents [<xref rid="B41-pharmacy-13-00067" ref-type="bibr">41</xref>]. The limited misuse of tapentadol relative to other Schedule II opioids [<xref rid="B6-pharmacy-13-00067" ref-type="bibr">6</xref>] may not be a sufficient advantage relative to another atypical opioid, tramadol, which is Schedule IV.</p><p>Recently, the German drugmaker Gr&#x000fc;nenthal was accused of conducting a disinformation campaign by promoting this Schedule II opioid [<xref rid="B42-pharmacy-13-00067" ref-type="bibr">42</xref>] as &#x0201c;not an opioid&#x0201d;, claiming that tapentadol has &#x0201c;minimum potential of abuse&#x0201d;, causes less dependence than other opioids, and &#x0201c;has no street value&#x0201d; and minimizing the potential for respiratory depression [<xref rid="B43-pharmacy-13-00067" ref-type="bibr">43</xref>]. Several converging lines of evidence have identified dopamine as integral to addiction, including for cocaine, amphetamine, nicotine, ethanol, and morphine [<xref rid="B44-pharmacy-13-00067" ref-type="bibr">44</xref>]. Intraperitoneal administration of tapentadol to rats evoked a pronounced (&#x0003e;600%) release of cortical dopamine [<xref rid="B45-pharmacy-13-00067" ref-type="bibr">45</xref>]. The street value of tapentadol from StreetRx.com in 2016 was USD 0.18/mg [<xref rid="B6-pharmacy-13-00067" ref-type="bibr">6</xref>] which, for the maximum daily dose (600 mg), would result in a non-trivial yearly diversion value (USD 39,420). A systematic review of studies published though 2017 identified ten overdoses involving tapentadol polysubsance use and four with only tapentadol [<xref rid="B36-pharmacy-13-00067" ref-type="bibr">36</xref>]. This included a 34-year-old Montana man with a history of IV drug use found gasping for breath by his wife. He did not have a prescription for tapentadol, and analytical chemistry did not detect any other substances of significance to this overdose [<xref rid="B46-pharmacy-13-00067" ref-type="bibr">46</xref>]. A 40-year-old man with a history of depression, anxiety, and a shoulder injury and a recent tapentadol prescription had heart blood tapentadol levels at over twenty-fold higher than the upper limit of the therapeutic range [<xref rid="B47-pharmacy-13-00067" ref-type="bibr">47</xref>]. These issues will warrant continued attention by opioid stewardship committees and others responsible for the judicious use of prescription opioids.</p></sec><sec sec-type="conclusions" id="sec5-pharmacy-13-00067"><title>5. Conclusions</title><p>This study quantified the dynamic pattern in tapentadol distribution from 2010 to 2020. Distributed tapentadol peaked in 2012. Thereafter, there has been a reduction in the distribution of tapentadol at both national and state levels. The declining tapentadol pattern is consistent with other opioids because, since 2011 [<xref rid="B7-pharmacy-13-00067" ref-type="bibr">7</xref>], there has been a steady decrease in the distribution of most medications used for pain [<xref rid="B8-pharmacy-13-00067" ref-type="bibr">8</xref>,<xref rid="B9-pharmacy-13-00067" ref-type="bibr">9</xref>,<xref rid="B10-pharmacy-13-00067" ref-type="bibr">10</xref>]. Tapentadol use showed clear regional differences in distribution which were significantly associated with diabetes prevalence. As tapentadol is the only Schedule II opioid that has dual MOR and monoamine transporter mechanisms, the role of this atypical opioid should continue to be evaluated, particularly within the framework of a disinformation campaign from the manufacturer downplaying the risk of addiction [<xref rid="B43-pharmacy-13-00067" ref-type="bibr">43</xref>], as well as the evolving US obesity and opioid epidemics.</p></sec></body><back><ack><title>Acknowledgments</title><p>Thanks to Iris Johnston for technical assistance.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, C.Y.L. and B.J.P.; methodology, C.Y.L. and K.L.M.; software, C.Y.L.; formal analysis, C.Y.L.; investigation, C.Y.L.; resources, B.J.P.; data curation, C.Y.L.; writing&#x02014;original draft preparation, C.Y.L.; writing&#x02014;review and editing, C.Y.L., K.L.M. and B.J.P.; visualization, C.Y.L. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was considered &#x0201c;exempt&#x0201d; by the IRBs of Geisinger (2021&#x02013;0313, Approved 21 April 2021) and the University of New England. (CR00001291, Approved 6 December 2022).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All data is publicly available from the ARCOS, Medicaid, and Medicare databases. ARCOS data is available at <uri xlink:href="https://www.medrxiv.org/content/10.1101/2022.03.03.22271869v1.supplementary-material">https://www.medrxiv.org/content/10.1101/2022.03.03.22271869v1.supplementary-material</uri> (accessed on 7 May 2025). Medicaid is available at <uri xlink:href="https://www.medicaid.gov/medicaid/prescription-drugs/state-drug-utilization-data/index.html">https://www.medicaid.gov/medicaid/prescription-drugs/state-drug-utilization-data/index.html</uri> (accessed on 7 May 2025). Medicare Part D is available at <uri xlink:href="https://data.cms.gov/provider-summary-by-type-of-service/medicare-part-d-prescribers/medicare-part-d-prescribers-by-geography-and-drug">https://data.cms.gov/provider-summary-by-type-of-service/medicare-part-d-prescribers/medicare-part-d-prescribers-by-geography-and-drug</uri> (accessed on 7 May 2025).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Author B.J.P. has received research grants from Pfizer and Eli Lilly. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">ARCOS</td><td align="left" valign="middle" rowspan="1" colspan="1">Automated Reports and Consolidated Orders System</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRNA</td><td align="left" valign="middle" rowspan="1" colspan="1">Certified Registered Nurse Anesthetist</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DEA</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug Enforcement Administration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ER</td><td align="left" valign="middle" rowspan="1" colspan="1">Extended Release</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FDA</td><td align="left" valign="middle" rowspan="1" colspan="1">Food and Drug Administration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MME</td><td align="left" valign="middle" rowspan="1" colspan="1">Morphine Mg Equivalent</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NDC</td><td align="left" valign="middle" rowspan="1" colspan="1">National Drug Code</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NP</td><td align="left" valign="middle" rowspan="1" colspan="1">Nurse Practitioner</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">US</td><td align="left" valign="middle" rowspan="1" colspan="1">United States</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-pharmacy-13-00067"><label>1.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Mann</surname><given-names>B.</given-names></name>
</person-group><article-title>More Than A Million Americans Have Died From Overdoses During The Opioid Epidemic. NPR</article-title><year>2021</year><comment>Available online: <ext-link xlink:href="https://www.npr.org/2021/12/30/1069062738/more-than-a-million-americans-have-died-from-overdoses-during-the-opioid-epidemi" ext-link-type="uri">https://www.npr.org/2021/12/30/1069062738/more-than-a-million-americans-have-died-from-overdoses-during-the-opioid-epidemi</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-01-08">(accessed on 8 January 2024)</date-in-citation></element-citation></ref><ref id="B2-pharmacy-13-00067"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rickli</surname><given-names>A.</given-names></name>
<name><surname>Liakoni</surname><given-names>E.</given-names></name>
<name><surname>Hoener</surname><given-names>M.C.</given-names></name>
<name><surname>Liechti</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Opioid-Induced Inhibition Of The Human 5-HT And Noradrenaline Transporters In Vitro: Link To Clinical Reports Of Serotonin Syndrome: Opioids and 5-HT</article-title><source>Br. J. Pharmacol.</source><year>2018</year><volume>175</volume><fpage>532</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1111/bph.14105</pub-id><pub-id pub-id-type="pmid">29210063</pub-id>
</element-citation></ref><ref id="B3-pharmacy-13-00067"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pop-Busui</surname><given-names>R.</given-names></name>
<name><surname>Boulton</surname><given-names>A.J.M.</given-names></name>
<name><surname>Feldman</surname><given-names>E.L.</given-names></name>
<name><surname>Bril</surname><given-names>V.</given-names></name>
<name><surname>Freeman</surname><given-names>R.</given-names></name>
<name><surname>Malik</surname><given-names>R.A.</given-names></name>
<name><surname>Sosenko</surname><given-names>J.M.</given-names></name>
<name><surname>Ziegler</surname><given-names>D.</given-names></name>
</person-group><article-title>Diabetic Neuropathy: A Position Statement By The American Diabetes Association</article-title><source>Diabetes Care</source><year>2017</year><volume>40</volume><fpage>136</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.2337/dc16-2042</pub-id><pub-id pub-id-type="pmid">27999003</pub-id>
</element-citation></ref><ref id="B4-pharmacy-13-00067"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>National Institute for Health and Care Excellence (NICE)</collab>
</person-group><source>Neuropathic Pain in Adults: Pharmacological Management in Non-Specialist Settings</source><publisher-name>National Institute for Health and Care Excellence (NICE)</publisher-name><publisher-loc>London, UK</publisher-loc><year>2020</year></element-citation></ref><ref id="B5-pharmacy-13-00067"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>Drug Enforcement Administration</collab>
</person-group><article-title>Schedules of Controlled Substances: Placement of Tapentadol into Schedule II [Internet]</article-title><source>Fed. Register.</source><year>2009</year><volume>74</volume><fpage>23790</fpage><lpage>23793</lpage><comment>Available online: <ext-link xlink:href="https://www.federalregister.gov/d/E9-11933" ext-link-type="uri">https://www.federalregister.gov/d/E9-11933</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-05">(accessed on 5 May 2025)</date-in-citation></element-citation></ref><ref id="B6-pharmacy-13-00067"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dart</surname><given-names>R.C.</given-names></name>
<name><surname>Surratt</surname><given-names>H.L.</given-names></name>
<name><surname>Le Lait</surname><given-names>M.C.</given-names></name>
<name><surname>Stivers</surname><given-names>Y.</given-names></name>
<name><surname>Bebarta</surname><given-names>V.S.</given-names></name>
<name><surname>Freifeld</surname><given-names>C.C.</given-names></name>
<name><surname>Brownstein</surname><given-names>J.S.</given-names></name>
<name><surname>Burke</surname><given-names>J.J.</given-names></name>
<name><surname>Kurtz</surname><given-names>S.P.</given-names></name>
<name><surname>Dasgupta</surname><given-names>N.</given-names></name>
</person-group><article-title>Diversion and Illicit Sale of Extended Release Tapentadol in the United States</article-title><source>Pain Med.</source><year>2015</year><volume>17</volume><fpage>1490</fpage><lpage>1496</lpage><pub-id pub-id-type="doi">10.1093/pm/pnv032</pub-id><pub-id pub-id-type="pmid">26814267</pub-id>
</element-citation></ref><ref id="B7-pharmacy-13-00067"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Collins</surname><given-names>L.K.</given-names></name>
<name><surname>Pande</surname><given-names>L.J.</given-names></name>
<name><surname>Chung</surname><given-names>D.Y.</given-names></name>
<name><surname>Nichols</surname><given-names>S.D.</given-names></name>
<name><surname>McCall</surname><given-names>K.L.</given-names></name>
<name><surname>Piper</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Trends in the Medical Supply of Fentanyl and Fentanyl Analogues: United States, 2006 to 2017</article-title><source>Prev. Med.</source><year>2019</year><volume>123</volume><fpage>95</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.ypmed.2019.02.017</pub-id><pub-id pub-id-type="pmid">30763629</pub-id>
</element-citation></ref><ref id="B8-pharmacy-13-00067"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Piper</surname><given-names>B.J.</given-names></name>
<name><surname>Shah</surname><given-names>D.T.</given-names></name>
<name><surname>Simoyan</surname><given-names>O.M.</given-names></name>
<name><surname>McCall</surname><given-names>K.L.</given-names></name>
<name><surname>Nichols</surname><given-names>S.D.</given-names></name>
</person-group><article-title>Trends in Medical Use of Opioids in the U.S., 2006&#x02013;2016</article-title><source>Am. J. Prev. Med.</source><year>2018</year><volume>54</volume><fpage>652</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1016/j.amepre.2018.01.034</pub-id><pub-id pub-id-type="pmid">29551331</pub-id>
</element-citation></ref><ref id="B9-pharmacy-13-00067"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boyle</surname><given-names>J.M.</given-names></name>
<name><surname>McCall</surname><given-names>K.L.</given-names></name>
<name><surname>Nichols</surname><given-names>S.D.</given-names></name>
<name><surname>Piper</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Declines and Pronounced Regional Disparities in Meperidine Use in the United States</article-title><source>Pharmacol. Res. Persp.</source><year>2021</year><volume>9</volume><fpage>e00809</fpage><pub-id pub-id-type="doi">10.1002/prp2.809</pub-id></element-citation></ref><ref id="B10-pharmacy-13-00067"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Furst</surname><given-names>J.A.</given-names></name>
<name><surname>Mynarski</surname><given-names>N.J.</given-names></name>
<name><surname>McCall</surname><given-names>K.L.</given-names></name>
<name><surname>Piper</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Pronounced Regional Disparities In United States Methadone Distribution</article-title><source>Ann. Pharmacother.</source><year>2022</year><volume>56</volume><fpage>271</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1177/10600280211028262</pub-id><pub-id pub-id-type="pmid">34184584</pub-id>
</element-citation></ref><ref id="B11-pharmacy-13-00067"><label>11.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Drug Enforcement Administration, Diversion Control Division</collab>
</person-group><article-title>ARCOS Retail Drug Summary Reports</article-title><comment>Available online: <ext-link xlink:href="https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/arcos-drug-summary-reports.html" ext-link-type="uri">https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/arcos-drug-summary-reports.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-07">(accessed on 7 May 2025)</date-in-citation></element-citation></ref><ref id="B12-pharmacy-13-00067"><label>12.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Drug Enforcement Administration, Diversion Control Division</collab>
</person-group><article-title>Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2025</article-title><comment>Available online: <ext-link xlink:href="https://www.deadiversion.usdoj.gov/quotas/quotas.html" ext-link-type="uri">https://www.deadiversion.usdoj.gov/quotas/quotas.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-07">(accessed on 7 May 2025)</date-in-citation></element-citation></ref><ref id="B13-pharmacy-13-00067"><label>13.</label><element-citation publication-type="gov"><article-title>State Drug Utilization Data. Medicaid.gov</article-title><comment>Available online: <ext-link xlink:href="https://www.medicaid.gov/medicaid/prescription-drugs/state-drug-utilization-data/index.html" ext-link-type="uri">https://www.medicaid.gov/medicaid/prescription-drugs/state-drug-utilization-data/index.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-05">(accessed on 5 May 2025)</date-in-citation></element-citation></ref><ref id="B14-pharmacy-13-00067"><label>14.</label><element-citation publication-type="gov"><article-title>Medicare Provider Utilization and Payment Data: Part D Prescriber. Centers for Medicare &#x00026; Medicaid Services</article-title><comment>Available online: <ext-link xlink:href="https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Part-D-Prescriber" ext-link-type="uri">https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Part-D-Prescriber</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-07-23">(accessed on 23 July 2021)</date-in-citation></element-citation></ref><ref id="B15-pharmacy-13-00067"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dowell</surname><given-names>D.</given-names></name>
<name><surname>Haegerich</surname><given-names>T.M.</given-names></name>
<name><surname>Chou</surname><given-names>R.</given-names></name>
</person-group><article-title>CDC Guideline For Prescribing Opioids For Chronic Pain&#x02014;United States</article-title><source>MMWR-Recomm. Rep.</source><year>2016</year><volume>65</volume><fpage>1</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.15585/mmwr.rr6501e1</pub-id></element-citation></ref><ref id="B16-pharmacy-13-00067"><label>16.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Robert Wood Johnson Foundation</collab>
</person-group><article-title>Diabetes in the United States. The State of Childhood Obesity</article-title><year>2021</year><comment>Available online: <ext-link xlink:href="https://stateofchildhoodobesity.org/" ext-link-type="uri">https://stateofchildhoodobesity.org/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-08-02">(accessed on 2 August 2021)</date-in-citation></element-citation></ref><ref id="B17-pharmacy-13-00067"><label>17.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Center for Drug Evaluation, Research</collab>
</person-group><article-title>National Drug Code Directory [Internet]. U.S. Food and Drug Administration</article-title><year>2020</year><comment>Available online: <ext-link xlink:href="https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory" ext-link-type="uri">https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-02-20">(accessed on 20 February 2022)</date-in-citation></element-citation></ref><ref id="B18-pharmacy-13-00067"><label>18.</label><element-citation publication-type="book"><source>Nucynta ER [Package Insert]</source><publisher-name>Collegium Pharmaceuticals</publisher-name><publisher-loc>Stoughton, MA, USA</publisher-loc><year>2021</year></element-citation></ref><ref id="B19-pharmacy-13-00067"><label>19.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>US Census Bureau</collab>
</person-group><article-title>Population</article-title><year>2012</year><comment>Available online: <ext-link xlink:href="https://www.census.gov/topics/population.html" ext-link-type="uri">https://www.census.gov/topics/population.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-02-20">(accessed on 20 February 2022)</date-in-citation></element-citation></ref><ref id="B20-pharmacy-13-00067"><label>20.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>CDC</collab>
</person-group><article-title>Prescription Painkiller Overdoses at Epidemic Levels [Internet]. CDC Online Newsroom&#x02014;Press Release: 1 November 2011</article-title><comment>Available online: <ext-link xlink:href="http://web.archive.org/web/20170711052446/https://www.cdc.gov/media/releases/2011/p1101_flu_pain_killer_overdose.html" ext-link-type="uri">http://web.archive.org/web/20170711052446/https://www.cdc.gov/media/releases/2011/p1101_flu_pain_killer_overdose.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-01-29">(accessed on 29 January 2022)</date-in-citation></element-citation></ref><ref id="B21-pharmacy-13-00067"><label>21.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention</collab>
</person-group><article-title>State Successes [Internet]</article-title><year>2019</year><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/overdose-prevention/site.html" ext-link-type="uri">https://www.cdc.gov/overdose-prevention/site.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-07">(accessed on 7 May 2025)</date-in-citation></element-citation></ref><ref id="B22-pharmacy-13-00067"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garc&#x000ed;a</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Declines In Opioid Prescribing After A Private Insurer Policy Change&#x02014;Massachusetts, 2011&#x02013;2015</article-title><source>MMWR Morbid Mortal. Wkly. Rep.</source><year>2016</year><volume>65</volume><fpage>1125</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6541a1</pub-id></element-citation></ref><ref id="B23-pharmacy-13-00067"><label>23.</label><element-citation publication-type="webpage"><article-title>Prescription Drug Monitoring Programs: Evolution and Evidence [Internet]. Penn LDI</article-title><year>2017</year><comment>Available online: <ext-link xlink:href="https://ldi.upenn.edu/our-work/research-updates/prescription-drug-monitoring-programs-evolution-and-evidence/" ext-link-type="uri">https://ldi.upenn.edu/our-work/research-updates/prescription-drug-monitoring-programs-evolution-and-evidence/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-01-18">(accessed on 18 January 2024)</date-in-citation></element-citation></ref><ref id="B24-pharmacy-13-00067"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>B.</given-names></name>
<name><surname>Zhao</surname><given-names>W.</given-names></name>
<name><surname>Yang</surname><given-names>K.C.</given-names></name>
<name><surname>Ahn</surname><given-names>Y.Y.</given-names></name>
<name><surname>Perry</surname><given-names>B.L.</given-names></name>
</person-group><article-title>Systematic Evaluation Of State Policy Interventions Targeting The US Opioid Epidemic, 2007&#x02013;2018</article-title><source>JAMA Netw. Open.</source><year>2021</year><volume>4</volume><fpage>e2036687</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.36687</pub-id><pub-id pub-id-type="pmid">33576816</pub-id>
</element-citation></ref><ref id="B25-pharmacy-13-00067"><label>25.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Ballotpedia</collab>
</person-group><article-title>Opioid Prescription Limits and Policies by State [Internet]</article-title><comment>Available online: <ext-link xlink:href="https://ballotpedia.org/Opioid_prescription_limits_and_policies_by_state" ext-link-type="uri">https://ballotpedia.org/Opioid_prescription_limits_and_policies_by_state</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-01-18">(accessed on 18 January 2024)</date-in-citation></element-citation></ref><ref id="B26-pharmacy-13-00067"><label>26.</label><element-citation publication-type="webpage"><article-title>New Hampshire Opioid Prescribing Resources [Internet]. New Hampshire Medical Society</article-title><comment>Available online: <ext-link xlink:href="https://www.nhms.org/Resources/Opioid-Substance-Related-Resources" ext-link-type="uri">https://www.nhms.org/Resources/Opioid-Substance-Related-Resources</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-01-18">(accessed on 18 January 2024)</date-in-citation></element-citation></ref><ref id="B27-pharmacy-13-00067"><label>27.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>National Institute on Drug Abuse</collab>
</person-group><article-title>Abuse NI on D. New Hampshire: Opioid-Involved Deaths and Related Harms [Internet]</article-title><year>2020</year><comment>Available online: <ext-link xlink:href="https://nida.nih.gov/drug-topics/opioids/opioid-summaries-by-state/new-hampshire-opioid-involved-deaths-related-harms#:~:text=In%202018%2C%20New%20Hampshire%20providers%20wrote%2046.1%20opioid" ext-link-type="uri">https://nida.nih.gov/drug-topics/opioids/opioid-summaries-by-state/new-hampshire-opioid-involved-deaths-related-harms#:~:text=In%202018%2C%20New%20Hampshire%20providers%20wrote%2046.1%20opioid</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-02-02">(accessed on 2 February 2022)</date-in-citation></element-citation></ref><ref id="B28-pharmacy-13-00067"><label>28.</label><element-citation publication-type="gov"><article-title>Treatment: Bureau of Drug and Alcohol Services: NH Department of Health and Human Services [Internet]. Treatment|Bureau of Drug and Alcohol Services|NH Department of Health and Human Services</article-title><comment>Available online: <ext-link xlink:href="https://web.archive.org/web/20220130074357/https://www.dhhs.nh.gov/dcbcs/bdas/treatment.htm" ext-link-type="uri">https://web.archive.org/web/20220130074357/https://www.dhhs.nh.gov/dcbcs/bdas/treatment.htm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-01-29">(accessed on 29 January 2022)</date-in-citation></element-citation></ref><ref id="B29-pharmacy-13-00067"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitra</surname><given-names>B.</given-names></name>
<name><surname>Roman</surname><given-names>C.</given-names></name>
<name><surname>Wu</surname><given-names>B.</given-names></name>
<name><surname>Luckhoff</surname><given-names>C.</given-names></name>
<name><surname>Goubrial</surname><given-names>D.</given-names></name>
<name><surname>Amos</surname><given-names>T.</given-names></name>
<name><surname>Bannon-Murphy</surname><given-names>H.</given-names></name>
<name><surname>Huyhn</surname><given-names>R.</given-names></name>
<name><surname>Dooley</surname><given-names>M.</given-names></name>
<name><surname>Smit</surname><given-names>D.V.</given-names></name>
<etal/>
</person-group><article-title>Restriction of oxycodone in the emergency department (ROXY-ED): A randomized controlled trial</article-title><source>Br. J. Pain</source><year>2023</year><volume>17</volume><fpage>491</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1177/20494637231189031</pub-id><pub-id pub-id-type="pmid">38107754</pub-id>
</element-citation></ref><ref id="B30-pharmacy-13-00067"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mirabella</surname><given-names>J.</given-names></name>
<name><surname>Ravi</surname><given-names>D.</given-names></name>
<name><surname>Chiew</surname><given-names>A.L.</given-names></name>
<name><surname>Buckley</surname><given-names>N.A.</given-names></name>
<name><surname>Chan</surname><given-names>B.S.</given-names></name>
</person-group><article-title>Prescribing Trend of Tapentadol in A Sydney Health District</article-title><source>Br. J. Clin. Pharmacol.</source><year>2022</year><volume>88</volume><fpage>3929</fpage><lpage>3935</lpage><pub-id pub-id-type="doi">10.1111/bcp.15448</pub-id><pub-id pub-id-type="pmid">35763675</pub-id>
</element-citation></ref><ref id="B31-pharmacy-13-00067"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McMichael</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Nurse practitioner scope-of-practice laws and opioid prescribing</article-title><source>Milbank Q.</source><year>2021</year><volume>99</volume><fpage>721</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1111/1468-0009.12524</pub-id><pub-id pub-id-type="pmid">34187087</pub-id>
</element-citation></ref><ref id="B32-pharmacy-13-00067"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lozada</surname><given-names>M.J.</given-names></name>
<name><surname>Raji</surname><given-names>M.A.</given-names></name>
<name><surname>Goodwin</surname><given-names>J.S.</given-names></name>
<name><surname>Kuo</surname><given-names>K.F.</given-names></name>
</person-group><article-title>Opioid prescribing by primary care providers: A cross-sectional analysis of nurse practitioner, physician assistant, and physician prescribing patterns</article-title><source>J. Gen. Intern. Med.</source><year>2020</year><volume>35</volume><fpage>2584</fpage><lpage>2592</lpage><pub-id pub-id-type="doi">10.1007/s11606-020-05823-0</pub-id><pub-id pub-id-type="pmid">32333312</pub-id>
</element-citation></ref><ref id="B33-pharmacy-13-00067"><label>33.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Sivek</surname><given-names>L.</given-names></name>
</person-group><article-title>Board of Nursing Prescriptive Authority [Internet]. Nhnpa.org</article-title><comment>Available online: <ext-link xlink:href="https://www.nhnpa.org/board-of-nursing-prescriptive-authority" ext-link-type="uri">https://www.nhnpa.org/board-of-nursing-prescriptive-authority</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-02-02">(accessed on 2 February 2022)</date-in-citation></element-citation></ref><ref id="B34-pharmacy-13-00067"><label>34.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Association of Nurse Practitioners</collab>
</person-group><article-title>NP Fact Sheet [Internet]. American</article-title><comment>Available online: <ext-link xlink:href="https://www.thenpa.org/page/npweek2021/1000#:~:text=There%20are%20more%20than%20325%2C000%20NPs%20licensed%20in%20the%20United%20States.&#x00026;text=More%20than%2036%2C000%20new%20NPs,academic%20programs%20in%202019%2D2020.&#x00026;text=88.9%25%20of%20NPs%20are%20certified,all%20NPs%20deliver%20primary%20care" ext-link-type="uri">https://www.thenpa.org/page/npweek2021/1000#:~:text=There%20are%20more%20than%20325%2C000%20NPs%20licensed%20in%20the%20United%20States.&#x00026;text=More%20than%2036%2C000%20new%20NPs,academic%20programs%20in%202019%2D2020.&#x00026;text=88.9%25%20of%20NPs%20are%20certified,all%20NPs%20deliver%20primary%20care</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-07">(accessed on 7 May 2025)</date-in-citation></element-citation></ref><ref id="B35-pharmacy-13-00067"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>N.</given-names></name>
</person-group><article-title>Learning Lessons: The Libby Zion Case Revisited</article-title><source>Am. Coll. Cardiol.</source><year>2014</year><volume>64</volume><fpage>2802</fpage><lpage>2804</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2014.11.007</pub-id></element-citation></ref><ref id="B36-pharmacy-13-00067"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Channell</surname><given-names>J.S.</given-names></name>
<name><surname>Schug</surname><given-names>S.</given-names></name>
</person-group><article-title>Toxicity Of Tapentadol: A Systematic Review</article-title><source>Pain Manag.</source><year>2018</year><volume>8</volume><fpage>327</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.2217/pmt-2018-0027</pub-id><pub-id pub-id-type="pmid">30079795</pub-id>
</element-citation></ref><ref id="B37-pharmacy-13-00067"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soares-Cardoso</surname><given-names>C.</given-names></name>
<name><surname>Leal</surname><given-names>S.</given-names></name>
<name><surname>Sa</surname><given-names>S.I.</given-names></name>
<name><surname>Dantas-Barros</surname><given-names>R.</given-names></name>
<name><surname>Dinis-Oliveira</surname><given-names>R.J.</given-names></name>
<name><surname>Faria</surname><given-names>J.</given-names></name>
<name><surname>Barbosa</surname><given-names>J.</given-names></name>
</person-group><article-title>Unraveling the hippocampal molecular and cellular alterations behind tramadol and tapentadol neurobehavioral toxicity</article-title><source>Pharmaceuticals</source><year>2024</year><volume>17</volume><elocation-id>796</elocation-id><pub-id pub-id-type="doi">10.3390/ph17060796</pub-id><pub-id pub-id-type="pmid">38931463</pub-id>
</element-citation></ref><ref id="B38-pharmacy-13-00067"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meneghini</surname><given-names>V.</given-names></name>
<name><surname>Cuccurazzu</surname><given-names>B.</given-names></name>
<name><surname>Bortolotto</surname><given-names>V.</given-names></name>
<name><surname>Ramazzotti</surname><given-names>V.</given-names></name>
<name><surname>Ubezio</surname><given-names>F.</given-names></name>
<name><surname>Tzschentke</surname><given-names>T.M.</given-names></name>
<name><surname>Grilli</surname><given-names>M.</given-names></name>
</person-group><article-title>The Noradrenergic Component In Tapentadol Counteracts -Opioid Receptor-Mediated Adverse Effects on Adult Neurogenesis</article-title><source>Mol. Pharmacol.</source><year>2014</year><volume>85</volume><fpage>668</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1124/mol.113.091520</pub-id></element-citation></ref><ref id="B39-pharmacy-13-00067"><label>39.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention</collab>
</person-group><source>National Diabetes Statistics Report, 2020</source><publisher-name>Centers for Disease Control and Prevention, U.S. Dept. of Health and Human Services</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2020</year></element-citation></ref><ref id="B40-pharmacy-13-00067"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Littlejohn</surname><given-names>G.O.</given-names></name>
<name><surname>Guyner</surname><given-names>E.K.</given-names></name>
<name><surname>Nglan</surname><given-names>G.S.</given-names></name>
</person-group><article-title>Is There A Role For Opioids In The Treatment Of Fibromyalgia?</article-title><source>Pain Manag.</source><year>2016</year><volume>6</volume><fpage>347</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.2217/pmt-2016-0012</pub-id><pub-id pub-id-type="pmid">27296831</pub-id>
</element-citation></ref><ref id="B41-pharmacy-13-00067"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eerdekens</surname><given-names>M.</given-names></name>
<name><surname>Radic</surname><given-names>T.</given-names></name>
<name><surname>Sohns</surname><given-names>M.</given-names></name>
<name><surname>Khalil</surname><given-names>F.</given-names></name>
<name><surname>Bulawa</surname><given-names>B.</given-names></name>
<name><surname>Elling</surname><given-names>C.</given-names></name>
</person-group><article-title>Outcomes of the Pediatric Development Plan of Tapentadol</article-title><source>J. Pain. Res.</source><year>2021</year><volume>14</volume><fpage>249</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.2147/JPR.S290487</pub-id><pub-id pub-id-type="pmid">33542654</pub-id>
</element-citation></ref><ref id="B42-pharmacy-13-00067"><label>42.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Jutkiewicz</surname><given-names>E.M.</given-names></name>
<name><surname>Traynor</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Opioid Analgesics</article-title><source>Goodman &#x00026; Gilman&#x02019;s: The Pharmacological Basis of Therapeutics</source><edition>14th ed.</edition><person-group person-group-type="editor">
<name><surname>Brunton</surname><given-names>L.L.</given-names></name>
<name><surname>Knollmann</surname><given-names>B.C.</given-names></name>
</person-group><publisher-name>McGraw-Hill Education</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2023</year><comment>Available online: <ext-link xlink:href="https://accessmedicine-mhmedical-com.gcsom.idm.oclc.org/content.aspx?bookid=3191&#x00026;sectionid=269719481" ext-link-type="uri">https://accessmedicine-mhmedical-com.gcsom.idm.oclc.org/content.aspx?bookid=3191&#x00026;sectionid=269719481</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-04">(accessed on 4 May 2025)</date-in-citation></element-citation></ref><ref id="B43-pharmacy-13-00067"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davies</surname><given-names>M.</given-names></name>
<name><surname>Boytchev</surname><given-names>H.</given-names></name>
<name><surname>Cabrera</surname><given-names>R.</given-names></name>
</person-group><article-title>Misleading Marketing Claims Fuel Tapentadol Prescriptions</article-title><source>Lancet</source><year>2025</year><volume>405</volume><fpage>963</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(25)00552-5</pub-id><pub-id pub-id-type="pmid">40122065</pub-id>
</element-citation></ref><ref id="B44-pharmacy-13-00067"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Solinas</surname><given-names>M.</given-names></name>
<name><surname>Belujon</surname><given-names>P.</given-names></name>
<name><surname>Fernagut</surname><given-names>P.O.</given-names></name>
<name><surname>Jaber</surname><given-names>M.</given-names></name>
<name><surname>Thiriet</surname><given-names>N.</given-names></name>
</person-group><article-title>Dopamine And Addiction: What Have We Learned From 40 Years Of Research</article-title><source>J. Neural Transm.</source><year>2018</year><volume>126</volume><fpage>481</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1007/s00702-018-1957-2</pub-id><pub-id pub-id-type="pmid">30569209</pub-id>
</element-citation></ref><ref id="B45-pharmacy-13-00067"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benade</surname><given-names>V.</given-names></name>
<name><surname>Nirogi</surname><given-names>R.</given-names></name>
<name><surname>Bhyrapuneni</surname><given-names>G.</given-names></name>
<name><surname>Daripelli</surname><given-names>S.</given-names></name>
<name><surname>Ayyanki</surname><given-names>G.</given-names></name>
<name><surname>Irappanavar</surname><given-names>S.</given-names></name>
<name><surname>Ponnamaneni</surname><given-names>R.</given-names></name>
<name><surname>Manoharan</surname><given-names>A.</given-names></name>
</person-group><article-title>Mechanistic Evaluation of Tapentadol in Reducing Pain Perception Using the In-vivo Brain and Spinal Cord Microdialysis in Rats</article-title><source>Eur. J. Pharmacol.</source><year>2017</year><volume>809</volume><fpage>224</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2017.04.013</pub-id><pub-id pub-id-type="pmid">28412373</pub-id>
</element-citation></ref><ref id="B46-pharmacy-13-00067"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kemp</surname><given-names>W.</given-names></name>
<name><surname>Schlueter</surname><given-names>S.</given-names></name>
<name><surname>Smalley</surname><given-names>E.</given-names></name>
</person-group><article-title>Death Due to Apparent Intravenous Injection of Tapentadol</article-title><source>J. Forensic Sci.</source><year>2013</year><volume>58</volume><fpage>288</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1111/j.1556-4029.2012.02299.x</pub-id><pub-id pub-id-type="pmid">23083009</pub-id>
</element-citation></ref><ref id="B47-pharmacy-13-00067"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Franco</surname><given-names>D.M.</given-names></name>
<name><surname>Ali</surname><given-names>Z.</given-names></name>
<name><surname>Levine</surname><given-names>B.</given-names></name>
<name><surname>Middleberg</surname><given-names>R.A.</given-names></name>
<name><surname>Fowler</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Case Report of a Fatal Intoxication by Nucynta</article-title><source>Am. J. Forensic Med. Pathol.</source><year>2014</year><volume>35</volume><fpage>234</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1097/PAF.0b013e3182887804</pub-id><pub-id pub-id-type="pmid">25384306</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmacy-13-00067-f001"><label>Figure 1</label><caption><p>Controlled substance distribution for tapentadol and other opioids from the Drug Enforcement Administration&#x02019;s Automated Reports and Consolidated Ordering System. (<bold>A</bold>) All Schedule II opioids declined, and tapentadol decreased by 53.8% from 2012 until 2020. (<bold>B</bold>) Comparison of DEA production quota and distribution. A <italic toggle="yes">t</italic>-test between distributed and final adjusted quota amounts of tapentadol was statistically significant (<italic toggle="yes">p</italic> &#x0003c; 0.05) for 2012&#x02013;2020. (<bold>C</bold>) Percentages of distributed Schedule II opioids in morphine mg equivalents (MME) for 2012 and 2020. (<bold>D</bold>) Tapentadol by retail distributors as a percentage of the total for 2010&#x02013;2020.</p></caption><graphic xlink:href="pharmacy-13-00067-g001" position="float"/></fig><fig position="float" id="pharmacy-13-00067-f002"><label>Figure 2</label><caption><p>Tapentadol (mg/person aged 18 and above) in various regional divisions using data from the Drug Enforcement Administration&#x02019;s Automated Reports and Consolidated Ordering System. (<bold>A</bold>) Time-series. (<bold>B</bold>) Regional analysis. Regions indicated with an n were statistically different from New England, whereas regions indicated with p were statistically different from Pacific (<italic toggle="yes">p</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="pharmacy-13-00067-g002" position="float"/></fig><fig position="float" id="pharmacy-13-00067-f003"><label>Figure 3</label><caption><p>Tapentadol distribution from the Drug Enforcement Administration&#x02019;s Automated Reports and Consolidated Ordering System. (<bold>A</bold>) Heatmap of percent change (mg/person) between 2012 and 2020. Only NH experienced a positive change (+13.1%). (<bold>B</bold>) Percent change between 2012 and 2020. The mean was &#x02212;51.7%, designated with a vertical dashed line, and the SD was 16.1%. States with a percentage change that was significantly different than the national average (* <italic toggle="yes">p</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="pharmacy-13-00067-g003a" position="float"/><graphic xlink:href="pharmacy-13-00067-g003b" position="float"/></fig><fig position="float" id="pharmacy-13-00067-f004"><label>Figure 4</label><caption><p>Scatterplot (r(50) = +0.80, <italic toggle="yes">p</italic> &#x0003c; 0.001) (<bold>A</bold>) and quarterly (<bold>B</bold>) prescribed tapentadol from Medicaid and distribution from ARCOS.</p></caption><graphic xlink:href="pharmacy-13-00067-g004" position="float"/></fig><fig position="float" id="pharmacy-13-00067-f005"><label>Figure 5</label><caption><p>Percent of Medicare Part D tapentadol claims by prescriber specialty. The difference from 2013 to 2019 is in parentheses after each specialty.</p></caption><graphic xlink:href="pharmacy-13-00067-g005" position="float"/></fig><fig position="float" id="pharmacy-13-00067-f006"><label>Figure 6</label><caption><p>Tapentadol claims in New Hampshire from Medicare Part D expressed as a percentage of each year by prescriber specialty. Nurse Practitioners prescribed 36.0% Medicare claims of tapentadol in 2019, followed by Pain Management (13.7%) and Physician Assistants (11.2%).</p></caption><graphic xlink:href="pharmacy-13-00067-g006" position="float"/></fig><fig position="float" id="pharmacy-13-00067-f007"><label>Figure 7</label><caption><p>Correlation between diabetes prevalence and tapentadol distribution for 2012 ((<bold>A</bold>) r(50) = 0.44, <italic toggle="yes">p</italic> &#x0003c; 0.01) and 2020 ((<bold>B</bold>) r(50) = 0.28, <italic toggle="yes">p</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="pharmacy-13-00067-g007" position="float"/></fig></floats-group></article>